JP2005512962A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005512962A5 JP2005512962A5 JP2003528864A JP2003528864A JP2005512962A5 JP 2005512962 A5 JP2005512962 A5 JP 2005512962A5 JP 2003528864 A JP2003528864 A JP 2003528864A JP 2003528864 A JP2003528864 A JP 2003528864A JP 2005512962 A5 JP2005512962 A5 JP 2005512962A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- designed
- sequence
- region
- library
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims 69
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 55
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 55
- 239000002131 composite material Substances 0.000 claims 15
- 239000012634 fragment Substances 0.000 claims 13
- 241000894007 species Species 0.000 claims 13
- 108091035707 Consensus sequence Proteins 0.000 claims 11
- 150000001413 amino acids Chemical class 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 230000005847 immunogenicity Effects 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 210000004602 germ cell Anatomy 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 238000004091 panning Methods 0.000 claims 2
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 208000010932 epithelial neoplasm Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000007312 paraganglioma Diseases 0.000 claims 1
- 210000004786 perivascular cell Anatomy 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000028210 stromal sarcoma Diseases 0.000 claims 1
- 206010042863 synovial sarcoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32353701P | 2001-09-20 | 2001-09-20 | |
| US32354401P | 2001-09-20 | 2001-09-20 | |
| US37999402P | 2002-05-13 | 2002-05-13 | |
| PCT/US2002/030086 WO2003025019A1 (en) | 2001-09-20 | 2002-09-20 | Anti-pdgf antibodies and methods for producing engineered antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005512962A JP2005512962A (ja) | 2005-05-12 |
| JP2005512962A5 true JP2005512962A5 (https=) | 2005-12-22 |
Family
ID=27406282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003528864A Withdrawn JP2005512962A (ja) | 2001-09-20 | 2002-09-20 | 抗ｐｄｇｆ抗体および設計抗体の産生方法 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1436329A4 (https=) |
| JP (1) | JP2005512962A (https=) |
| CA (1) | CA2460587A1 (https=) |
| WO (1) | WO2003025019A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002359568B2 (en) | 2001-12-03 | 2008-02-21 | Alexion Pharmaceuticals, Inc. | Hybrid antibodies |
| US7393648B2 (en) | 2001-12-03 | 2008-07-01 | Alexion Pharmaceuticals, Inc. | Hybrid antibodies |
| US20040009178A1 (en) * | 2002-02-11 | 2004-01-15 | Bowdish Katherine S. | Immunotherapeutics for biodefense |
| JP2007525458A (ja) * | 2003-04-23 | 2007-09-06 | メダレックス インコーポレイテッド | インターフェロンα受容体−１（ＩＦＮＡＲ−１）に対するヒト化抗体 |
| NZ592039A (en) * | 2003-08-27 | 2013-03-28 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
| EP1737890A2 (en) * | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| WO2009129538A2 (en) * | 2008-04-18 | 2009-10-22 | Xencor, Inc. | Human equivalent monoclonal antibodies engineered from nonhuman variable regions |
| WO2010099139A2 (en) | 2009-02-25 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Combination anti-cancer therapy |
| WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099364A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| NZ629697A (en) | 2012-03-15 | 2017-01-27 | Janssen Biotech Inc | Human anti-cd27 antibodies, methods and uses |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| WO2014001442A1 (en) * | 2012-06-28 | 2014-01-03 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| RU2676102C2 (ru) | 2012-09-27 | 2018-12-26 | Аллерган, Инк. | Биодеградируемые системы доставки лекарственных средств для долговременного высвобождения белков |
| JP6649246B2 (ja) | 2013-03-14 | 2020-02-19 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | タンパク質の徐放性送達の組成物及び製造プロセス中のタンパク質の安定化方法 |
| DK4374873T3 (da) | 2013-07-12 | 2025-11-03 | Astellas Us Llc | Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande |
| JP2019006732A (ja) * | 2017-06-27 | 2019-01-17 | 学校法人東京理科大学 | Ｍｙｃタンパク質阻害剤、Ｍｙｃタンパク質阻害方法、抗神経芽腫剤及びＭｙｃタンパク質の過剰発現を伴う疾患の治療方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5817310A (en) * | 1991-12-02 | 1998-10-06 | Cor Therapeutics, Inc. | Inhibitory immunoglobulin polypeptides to human PDGF beta receptor |
| US5976534A (en) * | 1993-02-25 | 1999-11-02 | Zymogenetics, Inc. | Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin |
| US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| WO1999024059A1 (en) * | 1997-11-07 | 1999-05-20 | Massachusetts Institute Of Technology | Pdgf-mediated microvascular communication and methods of use thereof |
| DK1034298T3 (da) * | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
-
2002
- 2002-09-20 WO PCT/US2002/030086 patent/WO2003025019A1/en not_active Ceased
- 2002-09-20 JP JP2003528864A patent/JP2005512962A/ja not_active Withdrawn
- 2002-09-20 EP EP02775937A patent/EP1436329A4/en not_active Withdrawn
- 2002-09-20 CA CA002460587A patent/CA2460587A1/en not_active Abandoned